Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 8, 2008

NextGen Acquires Pending Patent from Oxon Life Science Linked to Breast Cancer Stem Cells

  • NextGen Bioscience has obtained use, commercialization, and ownership rights of Oxon Life Science’s patent application related to cancer stem cells.

    The application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are usually resistant to conventional therapies, the companies explain.

    “Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies,” notes NextGen CEO, Konstantinos Kardiasmenos.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »